JAK/STAT EXPRESSION IN PATIENTS WITH IGA NEPHROPATHY

https://storage.unitedwebnetwork.com/files/1099/bb652950b943f4756c5d7d8654e8b166.pdf
JAK/STAT EXPRESSION IN PATIENTS WITH IGA NEPHROPATHY
Mateus
Luvizotto
Renato Monteiro renato.monteiro@inserm.fr Université Paris Cité & INSERM Département d'Hématologie et d'Immunologie de l’Hôpital Bichat Paris
Niels Olsen Camara niels@icb.usp.br Universidade de São Paulo Department of Immunology São Paulo
Luis Yu luisyu@usp.br Faculdade de Medicina da Universidade de São Paulo Department of Nephrology São Paulo
Cristiane Bitencourt Dias cristianebitencourt@uol.com.br Faculdade de Medicina da Universidade de São Paulo Department of Nephrology São Paulo
Lecticia Barbosa Jorge lecticiajorge@gmail.com Faculdade de Medicina da Universidade de São Paulo Department of Nephrology São Paulo
Viktoria Woronik viktoriaw@usp.br Faculdade de Medicina da Universidade de São Paulo Department of Nephrology São Paulo
 
 
 
 
 
 
 
 
 

The JAK/STAT signaling pathway is an intracellular signal transduction pathway, that is universally expressed and involved in diverse biological processes, including cell proliferation, differentiation, apoptosis and regulation of the immune system. Recent studies have explored abnormal receptor tyrosine kinase activation in the pathogenesis of IgA Nephropathy(IgAN).

       A retrospective study was performed between 2002 and 2016 in 63 patients with biopsy-proved IgAN.  Clinical and laboratory data were collected at baseline and at the end of follow up. Kidney tissue sections were stained with antibodies specific for components of JAK-STAT pathway. 

As controls 6 renal tumor border tissues were used. 


Clinical features are summarized in Table 1. Mean follow-up time in the study population was 102 months. More than half of patients achieved remission and 31.1% achieved the primary outcome primary outcome that was defined as end-stage renal disease (ESRD) or doubling of baseline creatinine. Staining for JAK3 was observed observed in the renal tubule and glomeruli. Staining for JAK3 was enhanced in patients with IgAN compared to controls.


Table 1 - Clinical and laboratory data at the time of biopsy and at the end of follow-up

n

63

Age (years)

33.00 [24.50-46.00]

Woman (n/%)

35 (55.6)

Not White (n/%)

17 (27.0)

Creatinine mg/dL

1.39 [0.94-2.21]

eGFR CKD-EPI (ml/min/1,73 m2)

58.00 [31.00-95.00]

Hematuria (n/%)

54(85.7)

Follow up (months)

102.00[34.00-144.50]

Remission n(%)

31(54.4)

Creatinine duplication or ESRD(%)

19(31.1)

Figure 1 - Comparison of JAK3 cell density in patients with IgAN and controls 

  

The presence of activation of the JAK/STAT signaling pathway has been demonstrated in patients with IgAN. This pathway may represent a therapeutic target in this pathology.


E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos